NCT00757562View on ClinicalTrials.gov

Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)

PHASE3CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

November 1, 2002

Primary Completion Date

October 1, 2003

Study Completion Date

October 1, 2003

Conditions
Chronic Idiopathic UrticariaAtopy
Interventions
DRUG

desloratadine

desloratadine syrup: 1.25 mg (2.5 mL) for subjects \>=2 to \<6 years, 2.5 mg (5 mL) for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.

DRUG

Placebo

placebo syrup: 2.5 mL for subjects \>=2 to \<6 years, 5 mL for subjects \>=6 to \<12 years, orally once daily in the morning for 36 days.

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00757562 - Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994) | Biotech Hunter | Biotech Hunter